Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Mechanism of action

5 evidence topics · 7 sources

Rationale for combined PKC and MET inhibition: hepatocyte growth factor in the liver and MET overexpression